AP5280

Known as: AP 5280 
 

Topic mentions per year

Topic mentions per year

2001-2009
01220012009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer conjugates containing doxorubicin designed in the late 1970s/early 1980s as… (More)
Is this relevant?
Review
2009
Review
2009
The concept of polymer-drug conjugates was proposed more than 30 years ago, and an N-(2-hydroxypropyl)methacrylamide (HPMA… (More)
Is this relevant?
2006
2006
AP5346 is a low molecular weight polymer-conjugated platinum antineoplastic agent. The lyophilized drug product has completed a… (More)
Is this relevant?
2004
2004
PURPOSE This Phase I study was designed to determine the maximum tolerated dose, profile of adverse events, and dose-limiting… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2004
2004
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the… (More)
Is this relevant?
2002
2002
AP5280 is an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer to which are linked tetrapeptide side chains containing bioactive… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2001
2001
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These… (More)
Is this relevant?